Clinical trial · Interventional
Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer
Prospective Study of Technical Optimization of the Detection of KRAS Mutations, BRAF and NRAS by Next Generation Sequencing on Tumor DNA Circulating in Metastatic Colorectal Cancer.
NCT02827565CI-TRIAL-00034225CircuLOR-1completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to optimize the search by next-generation sequencing (NGS) mutations in the KRAS, BRAF and NRAS on circulating tumor DNA and compare the genetic profiles obtained with those from tumors embedded in paraffin
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CircuLOR-1
- description
- KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations
- interventionNames
- Other: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
Primary outcomes (1)
- measure
- Technical Optimization of KRAS, BRAF and NRAS mutations detection
- timeFrame
- 1 day
- description
- Optimize the detection of mutations of KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAf (exon 15) genes, using the next-generation sequencing technology from circulating tumor DNA in patients with metastatic colorectal cancer.
Secondary outcomes (1)
- measure
- KRAS, NRAS et BRAF mutational status
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with metastatic or locally advanced colorectal carcinoma with a KRAS, BRAF or NRAS mutation * Age ≥ 18 years * Patient information and written informed consent form signed * Patient must be affiliated to a social security system Exclusion Criteria: * Patients whose health-cons indicates a blood sample 10mL * Age \< 18 years * Pregnant or breast feeding females * Persons deprived of liberty or under supervision
References
Publications (0)
Data not yet available
No reference posted for this study.